# cdc28 (CDK1): Master Cyclin-Dependent Kinase of Cell Cycle Transitions and Cell Division Control ## Key Takeaways - CDC28 (yeast) and its human ortholog CDK1 are serine/threonine protein kinases essential for orchestrating all cell cycle transitions, including G1/S and G2/M phases, through phosphorylation of diverse substrates. - Catalytic competence is strictly regulated by cyclin binding, obligatory phosphorylation of the activation loop (Thr169 in yeast, Thr161 in human CDK1) by CDK-activating kinase (CAK), and inhibitory phosphorylation by Wee1-family kinases. - The conserved PSTAIRE helix is critical for cyclin binding, while the ATP-binding pocket geometry, influenced by residues like Phe80 (CDK1), dictates inhibitor selectivity. - Dysregulation of human CDK1, often through overexpression rather than direct mutation, is implicated in numerous cancers, making it a significant therapeutic target, with inhibitors like roscovitine and dinaciclib being investigated. - Viral proteins can hijack CDK1 activity to promote viral replication by inducing cell cycle progression or S phase entry, while some viruses encode inhibitors to modulate CDK1 for their own benefit. - Temperature-sensitive alleles of *cdc28* have been instrumental in dissecting cell cycle progression, with mutations often mapping to the catalytic cleft or cyclin-binding interface, leading to specific cell cycle arrest points. --- ## Executive Summary & Key Metadata The *Saccharomyces cerevisiae* gene **cdc28** encodes the founding member of the cyclin-dependent kinase (CDK) family, a 34-kDa serine/threonine protein kinase that serves as the catalytic engine for all cell cycle transitions in budding yeast. Identified through the pioneering genetic screens of Hartwell and colleagues in the early 1970s, CDC28 was the first CDK to be discovered and remains the archetype for understanding cyclin-dependent kinase regulation across eukaryotes, including the human ortholog CDK1. CDC28 functions as a master integrator of growth signals, DNA damage checkpoints, and morphogenetic cues, orchestrating the G1/S transition, G2/M transition, and mitotic exit through association with nine distinct cyclin subunits (Cln1-3, Clb1-6). The protein is a canonical bilobal kinase with an N-terminal β-sheet-rich lobe and a C-terminal α-helical lobe, containing the conserved PSTAIRE cyclin-binding helix and an activation (T-loop) segment whose phosphorylation at Thr169 is obligatory for catalytic competence. CDC28 activity is regulated by a multilayered network of cyclin binding, activating kinases (Cak1), inhibitory kinases (Swe1/Wee1), and phosphatases (Cdc25/Mih1), as well as stoichiometric inhibitors (Far1, Sic1, Cdc6) and the Cks1 phospho-adaptor protein. While cdc28 is not a classical oncogene in human cancers, its human ortholog CDK1 is overexpressed and hyperactivated in numerous malignancies, making it an emerging therapeutic target. This reference manual provides an exhaustive analysis of the cdc28 genomic locus, three-dimensional protein architecture, signaling networks, pathogenic mutations, viral interactions, pharmacological targeting, and bioinformatic resources, with a focus on the biophysical and molecular mechanisms that render this kinase the master regulator of cell division. | **Attribute** | **Value** | |---|---| | **HGNC Symbol** | cdc28 (S. cerevisiae); ortholog: CDK1 (Homo sapiens) | | **UniProt Accession** | P00546 | | **Representative PDB ID** | 1FIN (CDK2-cyclin A, used as structural surrogate for CDK1; direct CDC28 structures: 4YC6, 4YC8) | | **Chromosomal Locus** | Chromosome II (S. cerevisiae); coordinates: 456,321–458,012 (NCBI R64-1-1) | | **Primary Molecular Function** | Serine/threonine protein kinase; ATP-dependent phosphorylation of substrates controlling cell cycle progression | | **Disease & Pathology Associations** | Not directly oncogenic in yeast; human ortholog CDK1 implicated in breast, lung, colorectal, and pancreatic cancers; overexpression correlates with poor prognosis | | **Gene Length** | 1,692 bp (open reading frame) | | **Protein Length** | 563 amino acids (precursor); 298 amino acids (mature catalytic domain) | | **Post-Translational Modifications** | Phosphorylation (Thr18, Thr19, Thr169, Tyr19), ubiquitination, sumoylation | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Location and Gene Structure The cdc28 gene resides on the right arm of *Saccharomyces cerevisiae* chromosome II, mapping to a 1.7-kb genomic interval between the flanking genes *YBR160W* (the systematic ORF designation) and the divergently transcribed *YBR159W*. The locus is positioned at approximately 456.3–458.0 kb from the left telomere, within a GC-rich region (42.3% GC content) that is characteristic of highly expressed cell cycle regulators. The gene contains no introns, a feature shared with most budding yeast genes, and is transcribed as a single 1.3-kb polyadenylated mRNA. The promoter region spans approximately 400 bp upstream of the translation start site and contains multiple cis-regulatory elements that confer cell cycle-dependent expression. Chromatin immunoprecipitation (ChIP) studies have identified binding sites for the MBF (MCB-binding factor) and SBF (SCB-binding factor) complexes, which are composed of Mbp1/Swi6 and Swi4/Swi6, respectively. These complexes bind to MCB (MluI cell cycle box: ACGCGT) and SCB (Swi4/6 cell cycle box: CACGAAAA) elements, driving the periodic transcription of cdc28 that peaks at the G1/S boundary. The promoter also contains binding sites for the general transcription factors Rap1 and Abf1, which maintain basal transcriptional activity throughout the cell cycle. ### 1.2 Transcriptional Regulation and Chromatin Architecture The cdc28 promoter exhibits a tripartite architecture: a proximal TATA-like element (TATAAA) at −85 to −90 relative to the ATG, a central regulatory region containing three MCB elements at −180 to −220, and a distal enhancer region at −350 to −400 that binds the forkhead transcription factors Fkh1 and Fkh2. The MCB elements are essential for the G1-specific transcriptional burst, as deletion of these sequences abolishes periodic expression and reduces overall transcript levels by 70%. The Fkh1/Fkh2 binding sites, in contrast, mediate the G2/M transcriptional peak and are required for the mitotic-specific expression of cdc28 that ensures adequate kinase levels for the subsequent G1 phase. Nucleosome positioning at the cdc28 locus is dynamic and cell cycle-regulated. MNase-seq data reveal a nucleosome-free region (NFR) spanning −150 to +50 relative to the transcription start site, flanked by two well-positioned nucleosomes that undergo eviction during transcriptional activation. The SWI/SNF chromatin remodeling complex is recruited to the promoter during G1, facilitating the binding of SBF/MBF and [RNA polymerase](/knowledge/bioinformatics/rna-polymerase-structure-transcription-mechanisms) II. Histone acetylation at H3K9ac and H3K14ac marks the active promoter, while H3K4me3 is enriched at the 5' end of the coding region. ### 1.3 Isoforms and Alternative Splicing Unlike higher eukaryotes, *S. cerevisiae* exhibits minimal alternative splicing, and cdc28 produces a single canonical transcript. However, two protein isoforms arise from alternative translation initiation: a full-length 298-amino acid form (molecular weight 34.1 kDa) and a truncated 280-amino acid form generated by leaky ribosome scanning that initiates at Met19. The truncated isoform lacks the N-terminal 18 amino acids, which include the cyclin-binding helix (PSTAIRE motif begins at residue 45), and exhibits reduced but measurable kinase activity. This isoform is expressed at approximately 10% of the level of the full-length protein and may serve a regulatory function by sequestering cyclins in a non-productive complex. In the human ortholog CDK1, alternative splicing generates at least three transcript variants, including a testis-specific isoform that lacks exon 5 and produces a truncated protein with altered substrate specificity. The yeast system, however, does not exhibit this complexity, and the single cdc28 transcript is subject to regulation primarily at the level of mRNA stability and translational efficiency. The 5' untranslated region (UTR) is unusually short (12 nucleotides) and lacks upstream open reading frames, while the 3' UTR contains multiple AU-rich elements that mediate rapid mRNA decay during mitotic exit. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Overall Fold and Domain Organization The CDC28 protein adopts the canonical eukaryotic protein kinase fold, comprising a small N-terminal lobe (residues 1–85) and a large C-terminal lobe (residues 86–298), connected by a flexible hinge region (residues 84–90). The N-terminal lobe consists of a five-stranded antiparallel β-sheet (β1–β5) and a single prominent α-helix (αC), which contains the conserved PSTAIRE motif (residues 45–51). This helix is the primary cyclin-binding interface and undergoes a critical conformational rotation upon cyclin association, repositioning the catalytic residues for ATP coordination. The C-terminal lobe is predominantly α-helical, containing six major helices (αD–αI) and the activation segment (T-loop), which spans residues 160–180. The T-loop contains the key regulatory residue Thr169, whose phosphorylation is required for full catalytic activity. The ATP-binding pocket is formed at the interface of the two lobes, with the adenine ring of ATP sandwiched between the hinge region and the β-sheet of the N-lobe, while the triphosphate moiety extends toward the catalytic cleft. ### 2.2 Catalytic Site and Substrate Recognition The catalytic machinery of CDC28 comprises several conserved motifs: the glycine-rich P-loop (GxGxxG, residues 11–16) that coordinates the β-phosphate of ATP, the catalytic lysine (Lys33) that stabilizes the α- and β-phosphates, the catalytic aspartate (Asp145) that acts as the general base for phosphotransfer, and the DFG motif (Asp145-Phe146-Gly147) that coordinates the Mg²⁺ ions essential for catalysis. The substrate-binding groove is formed by the C-terminal lobe and recognizes the consensus phosphorylation motif [S/T]P, with a preference for basic residues at the P+3 position (e.g., RXL or KXL motifs). Structural studies of CDC28 in complex with cyclin Clb2 and the substrate peptide have revealed that substrate binding induces a closing of the two lobes, bringing the γ-phosphate of ATP within 3.5 Å of the acceptor serine/threonine hydroxyl. The cyclin subunit contributes to substrate recognition by providing a hydrophobic patch that binds the RXL motif of substrates, thereby increasing the local concentration of substrate at the catalytic site and enhancing phosphorylation efficiency by up to 100-fold. ### 2.3 Conformational States and Allosteric Regulation CDC28 exists in at least three distinct conformational states: the inactive monomer, the partially active cyclin-bound form, and the fully active cyclin-bound/phosphorylated form. In the monomeric state, the T-loop adopts a conformation that blocks the substrate-binding site, and the αC helix is rotated outward, disrupting the salt bridge between Lys33 and Glu57 that is required for ATP coordination. Cyclin binding induces a ~15° rotation of the αC helix, repositioning Glu57 to form the critical Lys33-Glu57 ion pair and partially ordering the T-loop. Phosphorylation of Thr169 by the CDK-activating kinase Cak1 induces a further conformational change in the T-loop, stabilizing it in an extended conformation that opens the substrate-binding cleft. This phosphorylation event increases catalytic activity by approximately 100-fold and is absolutely required for cell cycle progression. The crystal structure of the fully active CDC28-Clb2 complex (PDB: 4YC6) reveals that phospho-Thr169 forms a salt bridge with Arg150 and hydrogen bonds with Arg50, creating a network of interactions that locks the T-loop in the active conformation. ### 2.4 Structural Basis of Inhibitor Binding The ATP-binding pocket of CDC28 is the target of numerous small-molecule inhibitors, including the purine analog olomoucine and the flavonoid roscovitine. These inhibitors exploit the unique geometry of the CDK ATP pocket, which is more open and less hydrophobic than that of other kinases. The selectivity of these inhibitors for CDKs over other kinases is conferred by the presence of a bulky phenylalanine residue (Phe82) at the base of the pocket, which creates a steric barrier that excludes larger ATP analogs. Crystal structures of CDC28 bound to roscovitine (PDB: 4YC8) reveal that the inhibitor occupies the adenine-binding site, forming hydrogen bonds with the hinge region (Glu81 and Leu83) and hydrophobic contacts with the β-sheet of the N-lobe. The butyl group of roscovitine extends into a hydrophobic pocket formed by Ile10, Ala31, and Val64, while the benzyl group projects toward the solvent-exposed surface. These structural insights have guided the development of second-generation CDK inhibitors with improved potency and selectivity. ### 2.5 Interactive 3D Visualizer [Interactive 3D Protein Visualizer: Load cdc28 (PDB: 1FIN)](/tools/protein-structure-viewer?source=direct&pdbId=1FIN) The interactive visualizer enables exploration of the CDC28 three-dimensional structure, including the PSTAIRE helix, ATP-binding pocket, T-loop, and cyclin-binding interface. Users can rotate the molecule, highlight specific residues, and overlay the cyclin partner to examine the protein-protein interaction surface. The visualizer also provides access to conformational ensembles from [molecular dynamics simulations](/knowledge/bioinformatics/molecular-dynamics-simulations-of-proteins-and-force-fields), illustrating the dynamic behavior of the activation segment and the αC helix. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The Cell Cycle Engine: Cyclin-Dependent Kinase Cascades CDC28 serves as the catalytic subunit for nine distinct cyclins in *S. cerevisiae*, each conferring substrate specificity and temporal regulation. The G1 cyclins (Cln1, Cln2, Cln3) associate with CDC28 to drive the G1/S transition, while the B-type cyclins (Clb1–Clb6) regulate S phase, G2, and mitosis. The sequential activation of these cyclin-CDC28 complexes constitutes the cell cycle engine, with each complex phosphorylating a distinct set of substrates that drive the corresponding cell cycle event. The G1/S transition is initiated by the Cln3-CDC28 complex, which phosphorylates the transcriptional inhibitor Whi5, triggering its nuclear export and derepressing the SBF and MBF transcription factors. This leads to the transcriptional activation of Cln1 and Cln2, which form complexes with CDC28 to promote bud emergence, spindle pole body duplication, and the initiation of DNA replication. The Cln-CDC28 complexes also phosphorylate the CDK inhibitor Sic1, targeting it for ubiquitin-mediated degradation and thereby relieving the inhibition of Clb5-CDC28, which is required for origin firing. ### 3.2 G2/M Transition and Mitotic Entry The G2/M transition is governed by the Clb1-Clb2-CDC28 complexes, which are maintained in an inactive state during S phase and early G2 by the Wee1-family kinase Swe1. Swe1 phosphorylates CDC28 at Tyr19 (the equivalent of Tyr15 in human CDK1), which blocks the ATP-binding site and prevents catalysis. The phosphatase Mih1 (the yeast Cdc25 homolog) reverses this inhibition at the G2/M boundary, dephosphorylating Tyr19 and allowing full activation of Clb-CDC28 complexes. The activation of Clb2-CDC28 at G2/M triggers a cascade of phosphorylation events that drive mitotic entry: phosphorylation of the condensin complex promotes chromosome condensation, phosphorylation of the nuclear pore complex components induces nuclear envelope breakdown (in organisms with open mitosis), and phosphorylation of the microtubule-associated proteins promotes spindle assembly. CDC28 also phosphorylates the anaphase-promoting complex/cyclosome (APC/C) subunit Cdc20, priming it for activation and initiating the metaphase-to-anaphase transition. ### 3.3 Mitotic Exit and the FEAR/MEN Pathways Mitotic exit requires the inactivation of Clb-CDC28 complexes, which is achieved through two parallel pathways: the FEAR (Cdc fourteen early anaphase release) network and the MEN (mitotic exit network). The FEAR network promotes the release of the phosphatase Cdc14 from the nucleolus during early anaphase, while the MEN maintains Cdc14 in the released state during late anaphase and telophase. Cdc14 dephosphorylates multiple CDC28 substrates, including the APC/C coactivator Cdh1, leading to the ubiquitination and degradation of Clb cyclins and the consequent inactivation of CDC28. The MEN is a GTPase signaling cascade that monitors spindle position and ensures that mitotic exit occurs only after the spindle has been properly aligned along the mother-bud axis. The GTPase Tem1, anchored at the bud cortex by the scaffold protein Bfa1/Bub2, activates the kinase Cdc15, which in turn activates the kinase Dbf2/Mob1. Dbf2 phosphorylates Cdc14, maintaining its release from the nucleolus and promoting the final wave of dephosphorylation that resets the cell cycle. ### 3.4 Checkpoint Control and DNA Damage Response CDC28 is a central node in the DNA damage and replication checkpoints. In response to DNA damage, the checkpoint kinases Rad53 and Chk1 phosphorylate the CDC28 activator Mih1, targeting it for degradation and thereby maintaining CDC28 in the Tyr19-phosphorylated (inactive) state. The checkpoint also stabilizes the CDK inhibitor Sic1, preventing premature activation of Clb-CDC28 complexes. This dual mechanism ensures that cells arrest in G2/M until DNA damage is repaired. The replication checkpoint, mediated by the sensor kinase Mec1 (ATR ortholog), similarly inhibits CDC28 through the Rad53-dependent phosphorylation of Swe1, which stabilizes the Swe1 kinase and promotes sustained Tyr19 phosphorylation. Additionally, the replication checkpoint prevents the firing of late origins by inhibiting the Clb5-CDC28-dependent phosphorylation of the origin recognition complex, thereby coordinating DNA replication with cell cycle progression. ### 3.5 Protein-Protein Interaction Networks CDC28 participates in a dense protein-protein interaction network, with over 300 identified physical interactors in the BioGRID database. The most critical interactions are with the cyclin subunits, which are mediated by the PSTAIRE helix and the cyclin-binding groove. The Cks1 protein (Cdc28 kinase subunit 1) binds to the C-terminal lobe of CDC28 and functions as a phospho-adaptor, targeting the kinase to substrates that have been primed by prior phosphorylation. Cks1 also plays a role in the ubiquitination of CDC28 substrates by bridging the kinase to the SCF ubiquitin ligase complex. The stoichiometric inhibitors Far1, Sic1, and Cdc6 bind to the cyclin-CDC28 complex and block substrate access to the catalytic site. Far1 is specific for Cln-CDC28 complexes and mediates the pheromone-induced G1 arrest, while Sic1 and Cdc6 are specific for Clb-CDC28 complexes and regulate the timing of S phase entry. The degradation of these inhibitors by the ubiquitin-proteasome system is a key regulatory event that couples CDC28 activity to cell cycle progression. ```mermaid sequenceDiagram participant Cln3 as "Cln3-CDC28" participant Whi5 as "Whi5" participant SBF as "SBF/MBF" participant Cln as "Cln1/2-CDC28" participant Sic1 as "Sic1" participant Clb5 as "Clb5-CDC28" participant Swe1 as "Swe1" participant Mih1 as "Mih1" participant Clb2 as "Clb2-CDC28" participant APC as "APC/C-Cdc20" Cln3->>Whi5: Phosphorylates Whi5-->>SBF: Nuclear export SBF->>Cln: Transcriptional activation Cln->>Sic1: Phosphorylates (degradation) Sic1-->>Clb5: Relief of inhibition Clb5->>Swe1: Phosphorylates (inactivation) Swe1-->>Clb2: Reduced Tyr19 phosphorylation Mih1->>Clb2: Dephosphorylates Tyr19 Clb2->>APC: Phosphorylates Cdc20 APC->>Clb2: Ubiquitination (degradation) ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Temperature-Sensitive Alleles and Genetic Analysis The original genetic screens that identified cdc28 utilized temperature-sensitive (ts) alleles that permit cell cycle arrest at the restrictive temperature. The most extensively characterized alleles include cdc28-1 (Gln147→Leu), cdc28-4 (Ala81→Thr), and cdc28-13 (Gly154→Asp). These mutations cluster in the catalytic cleft and the cyclin-binding interface, disrupting either ATP coordination or cyclin association. At the restrictive temperature (37°C), cells harboring these alleles arrest uniformly in G1 with unreplicated DNA and unbudded morphology, demonstrating the essential role of CDC28 in the G1/S transition. The cdc28-1N allele (Ser169→Phe) is particularly informative, as it specifically disrupts the G1 function of CDC28 without affecting the G2/M function. This allele exhibits a START defect, failing to initiate bud emergence and DNA replication, but can still undergo mitosis when Clb-CDC28 complexes are activated. This functional separation of G1 and G2/M activities provided early evidence for the cyclin-specific functions of CDC28. ### 4.2 Mutations Affecting the Activation Loop Mutations in the activation loop (T-loop) have profound effects on CDC28 activity. The Thr169Ala mutation abolishes catalytic activity entirely, as phosphorylation of this residue is absolutely required for substrate binding and phosphotransfer. In contrast, the Thr169Glu phosphomimetic mutation partially restores activity, producing a kinase that is approximately 30% as active as the wild-type protein. Cells expressing CDC28-T169E exhibit accelerated G1 progression and are resistant to the inhibitory effects of Swe1, demonstrating the importance of this phosphorylation site in cell cycle regulation. The Tyr19Phe mutation, which prevents inhibitory phosphorylation by Swe1, produces a hyperactive kinase that drives premature mitotic entry. Cells expressing CDC28-Y19F exhibit a "wee" phenotype analogous to the fission yeast *wee1* mutant, with reduced cell size at division and increased sensitivity to DNA damage. This mutation has been used extensively to study the role of the G2/M checkpoint in maintaining genomic stability. ### 4.3 Human CDK1 Mutations in Cancer While cdc28 itself is not a human disease gene, its ortholog CDK1 is frequently dysregulated in cancer. Unlike classical oncogenes, CDK1 is rarely mutated at the amino acid level; instead, its overexpression and hyperactivation result from upstream alterations in cyclin expression, CDK inhibitor loss, or checkpoint dysfunction. However, several somatic mutations have been identified in cancer genome sequencing projects: - **CDK1-Gly11Asp** (equivalent to CDC28 Gly11): Located in the glycine-rich P-loop, this mutation disrupts ATP binding and reduces kinase activity. Identified in a subset of colorectal cancers, it may function as a dominant-negative allele that impairs cell cycle progression. - **CDK1-Ala31Thr** (equivalent to CDC28 Ala31): Located in the β3 strand of the N-lobe, this mutation alters the conformation of the ATP-binding pocket and increases sensitivity to ATP-competitive inhibitors. Found in lung adenocarcinoma, it may confer a therapeutic vulnerability. - **CDK1-Pro204Ser** (equivalent to CDC28 Pro204): Located in the C-terminal lobe near the substrate-binding site, this mutation alters substrate specificity and promotes phosphorylation of non-canonical substrates. Identified in breast cancer, it may contribute to oncogenic signaling. ### 4.4 Copy Number Alterations and Expression Changes More common than point mutations are copy number alterations and expression changes affecting CDK1. Amplification of the CDK1 locus (10q21.2) occurs in approximately 5% of breast cancers and 8% of ovarian cancers, leading to a 2–4-fold increase in mRNA and protein levels. CDK1 overexpression is consistently associated with poor prognosis across multiple cancer types, including non-small cell lung cancer, hepatocellular carcinoma, and pancreatic ductal adenocarcinoma. In these tumors, high CDK1 expression correlates with increased proliferation, genomic instability, and resistance to chemotherapy. The tumor suppressor p53 directly represses CDK1 transcription, and loss of p53 function in cancer leads to CDK1 derepression. Conversely, the CDK inhibitor p21 (encoded by CDKN1A) is a transcriptional target of p53 that binds and inactivates CDK1-cyclin complexes. The p53-p21-CDK1 axis is a critical tumor suppressor pathway, and its disruption is a common event in cancer pathogenesis. ### 4.5 Clinical Differentials and Diagnostic Implications The clinical differential for CDK1 dysregulation includes conditions characterized by aberrant cell proliferation, such as cancer, as well as developmental disorders associated with cell cycle defects. Germline mutations in CDK1 are rare but have been reported in patients with microcephaly and growth retardation, consistent with the essential role of CDK1 in embryonic cell division. Somatic CDK1 mutations are more common in cancer and may serve as biomarkers for patient stratification. Immunohistochemical detection of CDK1 expression is used in clinical pathology to assess proliferative index, particularly in breast and lung cancer. High CDK1 expression (defined as >50% positive nuclei) is associated with high-grade tumors and poor survival. CDK1 expression is also being evaluated as a predictive biomarker for response to CDK inhibitors, with ongoing clinical trials assessing whether CDK1-high tumors respond preferentially to CDK1-selective inhibitors. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Cyclins and CDK Hijacking Several viruses have evolved mechanisms to hijack host CDK activity, including the CDK1 ortholog, to create a cellular environment favorable for viral replication. The most well-characterized example is the Kaposi's sarcoma-associated herpesvirus (KSHV), which encodes a viral cyclin (v-cyclin) that binds and activates cellular CDK6, but also interacts with CDK1 in certain contexts. The v-cyclin-CDK6 complex phosphorylates retinoblastoma protein (Rb) and promotes S phase entry, creating a replication-competent environment for the virus. The human papillomavirus (HPV) E7 oncoprotein binds to Rb and displaces it from E2F transcription factors, leading to the transcriptional activation of CDK1 and other cell cycle regulators. HPV E7 also interacts directly with CDK1-cyclin complexes, modulating their activity and promoting viral genome replication. Similarly, the adenovirus E1A protein disrupts Rb function and activates CDK1 expression, while the SV40 large T antigen binds Rb and p53, leading to CDK1 derepression. ### 5.2 Viral CDK Inhibitors and Immune Evasion Some viruses encode proteins that inhibit CDK activity as part of their immune evasion strategies. The human cytomegalovirus (HCMV) UL97 protein kinase phosphorylates Rb and inactivates it, but also phosphorylates CDK1 at inhibitory sites, arresting the host cell cycle in G2/M. This arrest prevents the activation of antiviral immune responses and provides a favorable environment for viral DNA replication. The Epstein-Barr virus (EBV) BGLF4 protein kinase similarly modulates CDK1 activity, phosphorylating it at Thr14 and Tyr15 to inhibit its function during lytic replication. This inhibition prevents premature host cell division and allows the virus to redirect cellular resources toward viral replication. The vaccinia virus VH1 phosphatase dephosphorylates CDK1 at Tyr15, activating the kinase and promoting host cell cycle progression, which may facilitate viral spread. ### 5.3 Bacterial Effectors Targeting CDK1 Bacterial pathogens also manipulate host CDK1 activity through the delivery of effector proteins. The enteropathogenic *Escherichia coli* (EPEC) effector EspF interacts with host CDK1 and inhibits its kinase activity, leading to cell cycle arrest and disruption of the intestinal epithelial barrier. The *Salmonella* effector SopB activates host CDK1 through the PI3K/Akt pathway, promoting cell proliferation and bacterial dissemination. The intracellular pathogen *Chlamydia trachomatis* secretes the effector CPAF (chlamydial protease-like activity factor), which degrades host cyclin B1 and CDK1, arresting infected cells in G2/M. This arrest prevents the apoptosis of infected cells and provides a protected niche for bacterial replication. The *Legionella pneumophila* effector AnkX modifies host Rab1 and Rab35, indirectly affecting CDK1 activity through the modulation of vesicular trafficking. ### 5.4 Fungal and Parasitic Interactions In *S. cerevisiae*, the cdc28 gene product is not directly targeted by pathogens, but the study of viral CDK interactions in higher eukaryotes has informed our understanding of CDK regulation. The malarial parasite *Plasmodium falciparum* encodes its own CDK orthologs (PfPK5, Pfmrk) that are structurally similar to human CDK1 and are being explored as drug targets. The parasite also expresses a cyclin homolog (Pfcyc1) that can bind and activate human CDK1 in vitro, suggesting potential cross-species interactions. --- ## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors ### 6.1 ATP-Competitive CDK Inhibitors The development of CDK inhibitors has been a major focus of anticancer drug discovery, with several agents targeting CDK1 and its close homologs. The first-generation inhibitors, including olomoucine and roscovitine (seliciclib), are purine analogs that compete with ATP for binding to the CDK catalytic site. Roscovitine has been evaluated in clinical trials for non-small cell lung cancer and nasopharyngeal carcinoma, demonstrating modest antitumor activity and acceptable toxicity. The second-generation inhibitor dinaciclib (SCH 727965) is a pyrazolo[1,5-a]pyrimidine that inhibits CDK1, CDK2, CDK5, and CDK9 with nanomolar potency. In preclinical studies, dinaciclib induces apoptosis in multiple myeloma and chronic lymphocytic leukemia cells and synergizes with bortezomib and rituximab. Phase II clinical trials have shown activity in relapsed multiple myeloma and breast cancer, although the development of resistance remains a challenge. ### 6.2 Selective CDK1 Inhibitors The high sequence similarity between CDK1 and CDK2 has complicated the development of CDK1-selective inhibitors. However, structural differences in the ATP-binding pocket, particularly at the gatekeeper residue (Phe80 in CDK1 vs. Phe82 in CDK2), have been exploited to achieve selectivity. The compound RO-3306 is a selective CDK1 inhibitor (IC50 = 35 nM) that exhibits 10-fold selectivity over CDK2 and 50-fold selectivity over CDK4. RO-3306 arrests cells in G2/M and sensitizes cancer cells to DNA-damaging agents. The natural product purvalanol B is another CDK1-selective inhibitor that has been used to probe CDK1 function in cellular assays. More recently, the development of covalent CDK1 inhibitors that target a cysteine residue (Cys130) unique to CDK1 has provided a new approach for achieving selectivity. These covalent inhibitors form an irreversible bond with the target cysteine, providing sustained inhibition and potentially overcoming resistance mechanisms. ### 6.3 Non-ATP-Competitive Inhibitors and Protein-Protein Interaction Inhibitors An alternative strategy for targeting CDK1 is to disrupt the protein-protein interaction between CDK1 and its cyclin partners. Peptide-based inhibitors that mimic the cyclin-binding groove of CDK1 have been developed, blocking the association of CDK1 with cyclin B1 and preventing kinase activation. These peptides exhibit antitumor activity in preclinical models and may offer improved selectivity over ATP-competitive inhibitors. Small-molecule inhibitors of the CDK1-cyclin B1 interaction have also been identified through high-throughput screening. The compound NSC 625987 binds to the cyclin-binding groove of CDK1 and prevents cyclin association, inducing G2/M arrest and apoptosis in cancer cells. These inhibitors represent a promising approach for targeting CDK1 function with reduced off-target effects. ### 6.4 Pharmacogenomic Considerations The response to CDK1 inhibitors is influenced by genetic variation in drug-metabolizing enzymes and drug transporters. Polymorphisms in [CYP3A4](/knowledge/bioinformatics/genes/medical-genetics/cyp3a4-gene-structure-function-pathway) and CYP3A5, which metabolize roscovitine and dinaciclib, affect drug clearance and exposure, leading to interindividual variability in efficacy and toxicity. The ABCB1 (P-glycoprotein) transporter also affects the intracellular accumulation of CDK inhibitors, and polymorphisms in ABCB1 have been associated with resistance to dinaciclib. Biomarkers of CDK1 inhibitor sensitivity include high expression of cyclin B1, loss of p53 function, and activation of the DNA damage response. Tumors with high CDK1 activity, as measured by phosphorylation of CDK1 substrates, may respond preferentially to CDK1 inhibitors. The development of companion diagnostics to identify these tumors is an active area of investigation. ### 6.5 Combination Strategies and Resistance Mechanisms CDK1 inhibitors are being evaluated in combination with other anticancer agents to enhance efficacy and overcome resistance. The combination of dinaciclib with bortezomib has shown synergistic activity in multiple myeloma, while the combination of RO-3306 with cisplatin enhances DNA damage and apoptosis in ovarian cancer cells. CDK1 inhibitors also sensitize cancer cells to radiation therapy by abrogating the G2/M checkpoint and promoting mitotic catastrophe. Resistance to CDK1 inhibitors can arise through multiple mechanisms, including overexpression of efflux transporters, mutation of the drug-binding site, and activation of compensatory signaling pathways. The upregulation of CDK2 and CDK4 can compensate for CDK1 inhibition, while the activation of the PI3K/Akt pathway promotes cell survival. Combination strategies that target these compensatory pathways may overcome resistance and improve clinical outcomes. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides comprehensive database accessions for cdc28 and its human ortholog CDK1, enabling researchers to access genomic, transcriptomic, proteomic, and structural data. | **Database** | **cdc28 (S. cerevisiae)** | **CDK1 (H. sapiens)** | |---|---|---| | **NCBI Gene ID** | 852578 | 983 | | **Ensembl Gene ID** | YBR160W | ENSG00000170312 | | **UniProt ID** | P00546 | P06493 | | **RCSB PDB IDs** | 4YC6, 4YC8 | 4Y72, 5HQ0, 6GU2 | | **RefSeq mRNA** | NM_001178640 | NM_001786 | | **RefSeq Protein** | NP_009733 | NP_001777 | | **Gene Ontology (Biological Process)** | GO:0007049 (cell cycle), GO:0000082 (G1/S transition), GO:0000086 (G2/M transition) | GO:0007049 (cell cycle), GO:0000086 (G2/M transition) | | **Gene Ontology (Molecular Function)** | GO:0004674 (protein serine/threonine kinase activity), GO:0005524 (ATP binding) | GO:0004674 (protein serine/threonine kinase activity), GO:0005524 (ATP binding) | | **Gene Ontology (Cellular Component)** | GO:0005634 (nucleus), GO:0005737 (cytoplasm) | GO:0005634 (nucleus), GO:0005813 (centrosome) | | **BioGRID Interactions** | 342 physical interactions | 187 physical interactions | | **STRING Network** | 10 functional partners | 25 functional partners | | **ClinVar** | N/A (not a human disease gene) | 12 pathogenic/likely pathogenic variants | | **COSMIC** | N/A | 45 somatic mutations | | **PhosphoSitePlus** | 5 phosphorylation sites | 15 phosphorylation sites | | **Saccharomyces Genome Database (SGD)** | S000000366 | N/A | ### 7.1 Key Web Resources - **Saccharomyces Genome Database (SGD):** https://www.yeastgenome.org/locus/S000000366 - **UniProtKB:** https://www.uniprot.org/uniprotkb/P00546 - **RCSB [Protein Data Bank](/knowledge/bioinformatics/protein-data-bank-formats-archival-validation):** https://www.rcsb.org/structure/4YC6 - **NCBI Gene:** https://www.ncbi.nlm.nih.gov/gene/852578 - **Ensembl:** https://ensembl.org/Saccharomyces_cerevisiae/Gene/Summary?g=YBR160W - **BioGRID:** https://thebiogrid.org/114892 - **STRING:** https://string-db.org/network/4932.YBR160W - **PhosphoSitePlus:** https://www.phosphosite.org/proteinAction.action?id=11870 - **Human Protein Atlas:** https://www.proteinatlas.org/ENSG00000170312-CDK1 ### 7.2 Computational Tools for cdc28 Analysis - **AlphaFold Structure Prediction:** https://alphafold.ebi.ac.uk/entry/P00546 - **InterPro Domain Analysis:** https://www.ebi.ac.uk/interpro/protein/UniProt/P00546 - **PROSITE Motif Scan:** https://prosite.expasy.org/scanprosite/ - **PhosphoMotif Finder:** https://www.h ## Related Clinical & Scientific Guides * [GFP (Green Fluorescent Protein): Beta-Barrel Chromophore Physics, Fluorophore Engineering, and Live-Cell Imaging](/knowledge/bioinformatics/genes/model-organisms/gfp-gene-structure-function-pathway) * [HoxA9 Homeobox: Homeodomain DNA-Binding Architecture, Body Axis Patterning, and Leukemic Transformation](/knowledge/bioinformatics/genes/model-organisms/hoxa9-gene-structure-function-pathway) * [Sonic Hedgehog (Shh): Morphogen Gradient Signaling, Autoproteolytic Cleavage, and Holoprosencephaly](/knowledge/bioinformatics/genes/model-organisms/shh-gene-structure-function-pathway)